New research about to get underway at the University of Virginia could help make life easier for people with Type One Diabetes- by possibly developing a fully automated insulin pump.
The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is ...
This research and delivery system will help patients with type 1 and type 2 diabetes receive their insulin based on real-time glucose levels.
Bernstein analyst Lee Hambright maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) yesterday and set a price target of ...
Bernstein analyst Lee Hambright raised the firm’s price target on Tandem Diabetes (TNDM) to $44 from $42 and keeps an Outperform rating on the ...
Zacks.com on MSN8d
Tandem Diabetes Forges New R&D Agreement With UVA: Stock to Gain?Tandem Diabetes Care, Inc. TNDM has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA). The partnership will focus on advancing research ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $95.91, ...
Today, Benzinga 's options scanner spotted 11 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...
CHICAGO, NY, UNITED STATES, January 17, 2025 /EINPresswire / -- The global insulin pump <a target=_blank href= ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback